Statements (31)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:small_molecule
gptkb:drug |
| gptkbp:approvalYear |
2019
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L01EX18
|
| gptkbp:brand |
Balversa
|
| gptkbp:CASNumber |
1346242-81-6
|
| gptkbp:chemicalFormula |
C25H30N6O2
|
| gptkbp:developedBy |
gptkb:Janssen_Pharmaceuticals
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
FGFR inhibitor
|
| gptkbp:molecularWeight |
446.55 g/mol
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
gptkb:eye
diarrhea fatigue dry mouth hyperphosphatemia stomatitis nail disorder |
| gptkbp:target |
gptkb:FGFR3
gptkb:FGFR1 gptkb:FGFR4 gptkb:FGFR2 |
| gptkbp:usedFor |
gptkb:urothelial_carcinoma
gptkb:cancer |
| gptkbp:bfsParent |
gptkb:FGFR1
gptkb:locally_advanced_or_metastatic_urothelial_carcinoma gptkb:FGFR3_gene |
| gptkbp:bfsLayer |
8
|
| https://www.w3.org/2000/01/rdf-schema#label |
erdafitinib
|